In a nutshell This study aimed to determine which patients benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination. Some background A main treatment option for prostate cancer is androgen deprivation...
Read More
In a nutshell This study looked at the safety and effectiveness of idelalisib treatment for patients with relapsed or difficult to treat follicular lymphoma. The study concluded that idelalisib can be used safely to treat these patients. Some background Follicular lymphoma (FL) is an incurable type of non-Hodgkin lymphoma. Patient outcomes...
Read More
In a nutshell The authors looked at the side effects and outcomes of the experimental treatment CAR-T biological therapy in the treatment of Hodgkin lymphoma. The authors concluded that CAR-T treatment is safe and can be beneficial for some patients. Some background Many new treatments are being developed to treat patients with relapsed...
Read More
In a nutshell This study aimed to investigate the safety and efficacy of bortezomib (Velcade) when combined with induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia. This study concluded that the combination of bortezomib and induction chemotherapy has high effectiveness but led to a high risk of infectious...
Read More
In a nutshell The authors looked at the effect of radiation therapy after autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma. The authors concluded that radiation therapy after autologous stem cell transplantation improved time to disease progression. Some background Hodgkin lymphoma (HL) is generally...
Read More
In a nutshell This phase 1 clinical trial will test the safety of isatuximab (SAR650984) in patients with relapsed or refractory multiple myeloma, as well as the effectiveness of isatuximab in multiple myeloma patients who have been previously treated with daratumumab (Darzalex). The primary outcome will be measured by side effects and overall...
Read More
In a nutshell This phase 1 clinical trial will test the safety of blinatumomab (Blincyto) treatment after high-dose melphalan (Alkeran) and autologous stem cell transplant in patients with refractory (unresponsive to treatment) multiple myeloma. The primary outcome will be measured by the number of adverse (negative) effects. The trial is being...
Read More
In a nutshell This paper compared the use of carfilzomib (Kyprolis) and bortezomib (Velcade) in the treatment of multiple myeloma. This study concluded that carfilzomib was associated with a reduced risk of death compared with bortezomib. Some background Multiple myeloma is a cancer of the plasma cells. New treatments have led to longer survival...
Read More
In a nutshell This study examined the safety and effectiveness of pembrolizumab in the treatment of chronic lymphocytic leukemia that has undergone Richter’s transformation. This study concluded that patients with Richter’s transformation responded to pembrolizumab. Some background Chronic lymphocytic leukemia is a cancer where...
Read More
In a nutshell This paper studied the effect of lymphodepletion chemotherapy and CAR-T cell infusion in patients with chronic lymphocytic leukemia who did not respond to ibrutinib (Imbruvica) therapy. This was found to be a highly effective treatment. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the blood forming cells....
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of an ibrutinib (Imbruvica) and rituximab (Rituxan) combination in treating patients with relapsed or refractory mantle cell lymphoma (MCL) or newly diagnosed elderly patients. The primary objective will be measured by the response rate. This trial is being conducted...
Read More
In a nutshell This phase 1 clinical trial will test the safety of a JCAR014 engineered T cells and durvalumab (MEDI4736) combination in treating recurrent or refractory (unresponsive to treatment) non-Hodgkin’s lymphoma. The primary outcome will be measured by evaluating the movement of the engineered T cells throughout the body and side...
Read More
